Evidence map›Paper›PMID 38952341›Full record

ArticleActa biochimica et biophysica Sinica2024

Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy.

Xinyi Cao, Zhihuang Hu, Xiangying Sheng, Zhenyu Sun, Lijun Yang, Hong Shu, Xiaojing Liu, Guoquan Yan, Lei Zhang, Chao Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.International journal of molecular sciences · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xinyi CaoInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Zhihuang HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiangying ShengDepartment of Chemistry, Fudan University, Shanghai 200433, China.
Zhenyu SunInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Lijun YangDepartment of Chemistry, Fudan University, Shanghai 200433, China.
Hong ShuDepartment of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Xiaojing LiuDepartment of Chemistry, Fudan University, Shanghai 200433, China.
Guoquan YanInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Lei ZhangInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Chao LiuBeijing Advanced Innovation Center for Precision Medicine, Beihang University, Beijing 100083, China.
Ying ZhangInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Huijie WangInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Haojie LuInstitutes of Biomedical Sciences and Shanghai Cancer Center, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) have significantly prolonged the survival of advanced/metastatic patients with lung cancer. However, only a small proportion of patients can benefit from ICIs, and clinical management of the treatment process remains challenging. Glycosylation has added a new dimension to advance our understanding of tumor immunity and immunotherapy. To systematically characterize anti-PD-1/PD-L1 immunotherapy-related changes in serum glycoproteins, a series of serum samples from 12 patients with metastatic lung squamous cell carcinoma (SCC) and lung adenocarcinoma (ADC), collected before and during ICIs treatment, are firstly analyzed with mass-spectrometry-based label-free quantification method. Second, a stratification analysis is performed among anti-PD-1/PD-L1 responders and non-responders, with serum levels of glycopeptides correlated with treatment response. In addition, in an independent validation cohort, a large-scale site-specific profiling strategy based on chemical labeling is employed to confirm the unusual characteristics of IgG N-glycosylation associated with anti-PD-1/PD-L1 treatment. Unbiased label-free quantitative glycoproteomics reveals serum levels' alterations related to anti-PD-1/PD-L1 treatment in 27 out of 337 quantified glycopeptides. The intact glycopeptide EEQFN

Indexed as

B7-H1 AntigenImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsProgrammed Cell Death 1 ReceptorAgedCarcinoma, Squamous CellFemaleGlycoproteinsGlycosylationHumansLipopolysaccharide-Binding ProteinMaleMiddle AgedB7-H1 AntigenCD274 protein, humanGlycoproteinsImmune Checkpoint InhibitorsLipopolysaccharide-Binding ProteinPDCD1 protein, humanProgrammed Cell Death 1 ReceptorglycopeptideIgGimmunotherapylung cancerPD-1/PD-L1

Identifiers

PMID38952341
PMCPMC11464919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.